



Tel: 971 4 398 8567 www.biosytech.com



Ms. SANGIMA RAI

PID NO: 43544

Age: 21 Years Sex: Female



Reference : Dr. AMAIZAH
Sample Collected At :

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

VID: 5050100662

Registered on:

02-May-2025 11:55 PM

Collected on : 02-May-2025 04:48 PM

Reported on :

03-May-2025 07:42 AM

Investigation

Observed Value

4.53

Flag Unit

Biological Reference Interval

* C-REACTIVE PROTEIN (CRP)

EACTIVE PROTEIN (CRP)

(Serum, Particle-enhanced immunoturbidimetric assay)

mg/L

< 5.0

Please note change. Source: Roche IFU.

INTERPRETATION:

- CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
- C-reactive protein is the classic acute phase protein in inflammatory reactions.
- CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently
 precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase
 begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma
 and severe infection (sepsis).
- CRP response may be less pronounced in patients suffering from liver disease.
- CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and
 Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to
 differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically
 monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected
 wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection."

----- End Of Report -----

ayana V. Shah DR. VYOMA SHAH

DR. ADLEY MARK FERNANDES D
M.D (Pathology) M
Pathologist CI

This is an Electronically Authenticated Report.

Page 1 of 1

M.D (Pathology) Clinical Pathologist

HALEEM HAKKIM Laboratory Technician

Printed on:

05-May-2025 05:38 PM

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (*).

CAP ACCREDITED



Off.1, Mezzanine Floor, Muzoon Bldg - 294, Al Karama

Post Box No. 49527 Dubai UAE

info@biosytech.ae